NCRBF yields 3.81% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, NCRBF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NCRBF + PFE for your $10,000?
Nippon Carbon Co., Ltd. engages in the manufacture and sale of carbon products in Japan. It offers carbon fiber products, including molded heat insulating materials for high temperature furnaces; CARBORON, a soft felt used in a range of heat insulators for high temperature furnaces; C/C Composite, a lightweight carbon material used in heat resistant composite structural members, high temperature furnace materials, trays, jigs, etc.; and CARBEST, a carbon fiber packing material. The company also provides specialty carbon products, such as isotropic graphite, a graphite material; high purity treatment graphite used for manufacturing device components for silicon semiconductors, compound semiconductors, and optical fibers; carbon products for mechanical components that are used in various fields of science, including electronics, machinery, and the metallurgy industry; VESCOAT, a silicon carbide coated product used for silicon semiconductor, LED, and manufacturing device components for optical fibers; and SC CARBON sliding composites. In addition, it offers artificial graphite electrodes for use in high-power electric arc furnaces; silicon carbide continuous fibers, such as Nicalon, Hi-Nicalon, and Hi-Nicalon TypeS for use as reinforcement fibers in ceramic composite materials, plastic composite materials, and others; and lithium ion secondary batteries used for cellular and smart phones, NBPC, tablet terminals, power tools, hybrid automobiles, and electric automobiles. Further, the company provides impervious graphite RESBON, a corrosion-resistant material; NICABEADS, which are surface-coated micro bead-shape materials; and NICAFILM, a flexible graphite sheet made from natural graphite. The company was incorporated in 1915 and is headquartered in Tokyo, Japan.
Full NCRBF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.